The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); Roche (Inst)
 
Javier Cortes
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Merus; Roche
 
Jonas C. S. Bergh
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Other Relationship - UpToDate
 
Lajos Pusztai
Honoraria - Almac Diagnostics; AstraZeneca/MedImmune; Merck; Pfizer; pfizer; Syndax
Consulting or Advisory Role - H3 Biomedicine; Merck; Novartis; PierianDx; Seagen; Syndax
Research Funding - AstraZeneca; Genentech; Merck; Seagen
 
Carsten Denkert
Stock and Other Ownership Interests - Sividon Diagnostics
Honoraria - Amgen; Novartis; Pfizer; Roche; Teva
Consulting or Advisory Role - Amgen; MSD Oncology
Patents, Royalties, Other Intellectual Property - Predictive gene expression signature for therapy response; VMScope digital pathology software
 
Sunil Verma
Leadership - Oncology Education
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Novartis; Pfizer; Roche/Genentech; Spectrum Pharmaceuticals
 
Heather L. McArthur
Consulting or Advisory Role - Amgen; Calithera Biosciences; Lilly; Merck; OBI Pharma; Peregrine Pharmaceuticals; Roche; Spectrum Pharmaceuticals; Syndax; TapImmune Inc.
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); ZIOPHARM Oncology (Inst)
Travel, Accommodations, Expenses - Amgen; Calithera Biosciences; Lilly; Merck; OBI Pharma; Roche; Spectrum Pharmaceuticals
Other Relationship - Lilly; OBI Pharma
 
Sherko Kummel
Honoraria - Amgen; Celgene; Daiichi Sankyo; Novartis; Roche
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Celgene; Roche
 
Yu Ding
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Vassiliki Karantza
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Thao Dang
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Rebecca Alexandra Dent
Honoraria - AstraZeneca; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Eisai; Merck; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche